U.S. License Holder:
Galderma Labs LP
Date of License:
August-12-2024 [December-13-2024]
Last Update:
Dec-15-2024
FDA-Approved Indications
[BL761390] NEMLUVIO (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis.
[BL 761391] NEMLUVIO (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.